Abstract
Drug resistance is a major obstacle to effective TB control program performance. In this study, we assessed the prevalence of primary drug resistance in Mycobacterium tuberculosis (Mtb) isolates in Amhara Region, Ethiopia. A total of 112 Mtb isolates from cases with newly diagnosed pulmonary TB were subjected to drug susceptibility testing (DST) in a cross-sectional study. Isolates were tested for sensitivity to isoniazid, rifampicin, ethambutol, and streptomycin using the MGIT 960 protocol. A total of 93 Mtb isolates yielded valid DST results and 28 (30.1%) were resistant to one or more of first line anti-TB drugs. One isolate (1.0%) was multi-drug resistant (MDR), five (5.4%) were classified as poly-resistant and 22 showed single drug resistance to either streptomycin (n = 19) or isoniazid (n = 3). Isolates from HIV-positive patients were more likely to be resistant to at least one of the four anti-TB drugs compared with HIV-negative individuals (odds ratio 2.76, 95% confidence interval 1.06-7.22; p = 0.03). The study showed a high prevalence of primary drug resistance. Even though the prevalence of MDR was low, conditions that can contribute to the development of MDR are increasing. Therefore, regular monitoring of drug resi...Continue Reading
References
Apr 1, 1992·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·K Weyer, H H Kleeberg
Jul 27, 2001·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·W P PintoM A Basile
Mar 1, 2002·Scandinavian Journal of Infectious Diseases·M DemissieB Lindtjorn
Dec 14, 2005·BMC Infectious Diseases·Solomon YimerGetu Alene
Mar 7, 2006·Journal of Clinical Microbiology·Sabine Rüsch-GerdesSalman Siddiqi
Dec 19, 2006·The Journal of School Nursing : the Official Publication of the National Association of School Nurses·Joellyn RandallCynthia Galemore
Jul 30, 2008·BMC Infectious Diseases·Benon B AsiimweMoses L Joloba
Apr 3, 2009·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Mecky MateeCarol Holm-Hansen
Apr 21, 2009·Lancet·Abigail WrightUNKNOWN Global Project on Anti-Tuberculosis Drug Resistance Surveillance
Nov 21, 2009·Clinics in Chest Medicine·Giovanni Battista MiglioriChristoph Lange
Dec 17, 2009·BMC Public Health·Solomon YimerGunnar Bjune
May 22, 2010·Lancet·Neel R GandhiJaime Bayona
May 5, 2011·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Po-Ren Hsueh
May 12, 2011·The Journal of Antimicrobial Chemotherapy·Pedro Eduardo Almeida Almeida Da Silva, Juan Carlos Palomino
Jul 30, 2011·PloS One·Jason E FarleyMartie Van der Walt
Citations
Dec 7, 2013·Ethiopian Journal of Health Sciences·Asres BerhanDesalegn Yizengaw
Dec 20, 2014·BMC Infectious Diseases·Nicholas EzatiMoses L Joloba
May 17, 2014·Tuberculosis Research and Treatment·Berhanu SeyoumAbraham Aseffa
Jul 17, 2015·Tuberculosis Research and Treatment·Minwuyelet MaruAbraham Aseffa
Jun 21, 2015·BMC Public Health·Kelemework AdaneAbraham Aseffa
Apr 17, 2015·BMC Public Health·Deus LukoyeGabriela B Gomez
Jul 5, 2017·Trials·Ruixue HuangJianan Hu
Sep 26, 2017·PloS One·Baba Maiyaki MusaMuktar H Aliyu
Feb 17, 2015·Antimicrobial Resistance and Infection Control·Fantahun BiadglegneArne C Rodloff
Jun 25, 2019·PloS One·Delesa DamenaGobena Ameni
Dec 5, 2017·Global Health Research and Policy·Yohannes Teka MazeingiaYadeta Dessie
Apr 9, 2020·PloS One·Tekle Airgecho LobieAbraham Aseffa
Mar 23, 2017·BMC Infectious Diseases·Setegn EshetieFeleke Moges
Oct 31, 2019·Pathogens·Tuelo MogashoaSimani Gaseitsiwe
Aug 17, 2020·PloS One·Letemichael Negash WelekidanSolomon Abebe Yimer
Jul 20, 2016·BMC Public Health·Shallo Daba HamusseBernt Lindtjørn
Jun 1, 2018·Journal of Pathogens·Solomon Weldegebreal AsgedomHailay Gebreyesus
Nov 17, 2016·International Journal of Mycobacteriology·Kebede TesfayKelemework Adane
Jun 27, 2018·Tropical Diseases, Travel Medicine and Vaccines·Tadele GirumMisgun Shewangizaw
Aug 31, 2019·Advances in Preventive Medicine·Alemayehu RetaAbeba Mengist
Aug 12, 2014·BMC Research Notes·Wassihun WedajoAbraham Aseffa